Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series

United European Gastroenterology Journal

Volumn 4, Issue 1, 2016, Pages 97-104

  Greuter, Thomas ^a   Biedermann, Luc ^a   Rogler, Gerhard ^a   Sauter, Bernhard ^b   Seibold, Frank ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b GastroZentrum Hirslanden   (Switzerland)

^c Spital Bern Tiefenau   (Switzerland)

Author keywords

Alicaforsen; Antisense oligonucleotide; Chronic pouchitis; ICAM 1; Inflammatory bowel disease; Relapse

Indexed keywords

ALICAFORSEN; C REACTIVE PROTEIN; CALGRANULIN; CIPROFLOXACIN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; MESALAZINE; METRONIDAZOLE; MUTAFLOR; PROBIOTIC AGENT; STEROID;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; DEMOGRAPHY; DISEASE ACTIVITY; ENDOSCOPY; EVALUATION AND FOLLOW UP; EVENING DOSAGE; FECES ANALYSIS; FEMALE; HISTOLOGY; HUMAN; ILEITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROCTOCOLECTOMY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84979462428     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640615593681     Document Type: Article

References (23)

1. Mosli MH, Rivera-Nieves J and Feagan BG. T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: Current and future prospects. Drugs 2014; 74: 297-311.
2. Cottone M, Renna S, Orlando A, et al. Medical management of Crohn's disease. Expert Opin Pharmacother 2011; 12: 2505-2525.
3. Rivera-Nieves J, Gorfu G and Ley K. Leukocyte adhesion molecules in animal models of inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1715-1735.
4. Dustin ML, Rothlein R, Bhan AK, et al. Induction by IL-1 and interferon-gamma: Tissue distribution, biochemistry and function of a natural adherence molecule (ICAM-1). J Immunol 1986; 137: 245-254.
5. Carlos TM and Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994; 84: 2068-2101.
6. Barish CF. Alicaforsen therapy in inflammatory bowel disease. Expert Opin Biol Ther 2005; 5: 1387-1391.
7. Gewirtz AT and Sitaraman S. Alicaforsen. Curr Opin Investig Drugs 2001; 2: 1401-1406.
8. Yacyshyn BR, Barish C, Goff J, et al. Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. Aliment Pharmacol Ther 2002; 16: 1761-1770.
9. Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo-controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid-dependent Crohn's disease. Gut 2002; 51: 30-36.
10. Yacyshyn B, Chey WY, Wedel MK, et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 2007; 5: 215-220.
11. Van Deventer SJ, Wedel MK, Baker BF, et al. A Phase II dose-ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1415-1425.
12. Miner PB, Wedel MK, Xia S, et al. Safety and efficacy of two dose formulations of alicaforsen enema, compared with mesalazine enema, for treatment of mild-to-moderate left-sided ulcerative colitis: A randomized, doubleblind, active-controlled trial. Aliment Pharmacol Ther 2006; 23: 1403-1413.
13. Miner P, Wedel M, Bane B, et al. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 2004; 19: 281-286.
14. Mahadevan U and Sandborn WJ. Diagnosis and management of pouchitis. Gastroenterology 2003; 124: 1636-1650.
15. Sandborn WJ. Trends in inflammatory bowel disease 1996. In: McLeod RS Martin F, Sutherland LR, et al. (eds) Lancaster, PA: Kluwer Academic Publishers; 1997.
16. Patel RT, Pall AA, Adu D, et al. Circulating soluble adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995; 7: 1037-1041.
17. Sandborn WJ, Tremaine WJ, Batts KP, et al. Pouchitis after ileal pouch-anal anastomosis: A Pouchitis Disease Activity Index. Mayo Clin Proc 1994; 69: 409-415.
18. Moskowitz RL, Shepherd NA and Nicholls RJ. An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir. Int J Colorectal Dis 1986; 1: 167-174.
19. Ford AC, Khan KJ, Achkar J-P, et al. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: Systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 167-176.
20. Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX extended-release tablets induce remission in patients with mild-to-moderate ulcerative colitis: Results from the CORE I study. Gastroenterology 2012; 143: 1218-1226.
21. Monteleone G, Neurath M, Ardizzone S, et al. OP203 mongersen, an oral SMAD7 antisense oligonucleotide, in active Crohn's disease. United Europ Gastroenterol J 2014; 2: A65.
22. Lobaton T, Vermeire S, Van Assche G, et al. Review article: Anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Therapeut 2014; 39: 579-594.
23. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710.